Please tell us about your clinical experience. How many patients with opioid withdrawal symptoms do you see yearly? What is the available choice of treatment,for the most common opioid medicines like Oxycontin, Vicodin or Dilaudid?

After slowly reducing opioids in the first instance, what percent of the patients require further treatments aimed at the symptoms?

Is full detoxification from opioids only achieved in transitioning a patient to the opioid antagonist intramuscular naltrexone; vs transitioning to either methadone or buprenorphine, will it still maintain the patient in a state of physiological dependence on opioid agonism?

BXCL501 reported 6 orthostatic hypotension adverse events at higher than 120 mcg doses. Also, 46.7% of patients on 240 mcg dose presented with somnolence after treatment. Does any of that worry you?

The 120 mcg and 180 mcg dose groups showed 42% and 52% rates of retention at Day 6 of BXCL501 treatment, respectively, versus 24% for placebo, though observations were not statistically significant. The results also showed that of the 87% of patients who had fentanyl in their systems upon entry, greater than 50% remained fentanyl positive following the morphine stabilization phase of 5 days. What are your comments on these results?

How would you assess the overall potential of BXCL501 as a non-opioid based treatment option? Where do you see its main competition coming from, and where might obstacles present themselves?

How likely would you be to prescribe BXCL501 for Opioid Withdrawal Symptoms?